Correction: Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings
نویسندگان
چکیده
Following the publication of the above article [1], we noticed that the Competing interests section was incorrect and should read as follows: RMG has worked as a consultant for Novo Nordisk and lectured on behalf of Novo Nordisk about NovoSeven. References 1. Grounds RM, Bolan C: Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings.
منابع مشابه
Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings
The hemostatic properties of recombinant activated factor VII (rFVIIa) are established in patients with inherited or acquired hemophilia with inhibitors and in patients with congenital factor VII deficiencies. Emerging clinical evidence suggests that there may be a wider role for rFVIIa in the management of hemorrhage associated with traumatic injury/accident and severe bleeding associated with...
متن کاملHemorrhage Treatment Report of Patients Suffering from Glanzmann’s Thrombasthenia Resulting Hospitalization from 2006 to 2011 at Mofid Children’s Hospital
Background: The present study evaluated treatment outcomes and the treatment indexes among Glanzmann’s patients in Mofid Children’s Hospital, Tehran, Iran. Patients and Methods: A retrospective cross-sectional study was performed to evaluate the treatment protocols on 15 Glanzmann’s patients with bleeding therapeutic records in Mofid Children’s Hospital, Tehran, Iran, from 2006 to 2011. Resu...
متن کاملEfficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review.
BACKGROUND Recombinant activated factor VII (factor VIIa) is a prohemostatic agent that can be used for patients with complicated coagulation disorders. Recombinant factor VIIa is, however, increasingly used for several other indications, including patients with a preexistent normal coagulation system but who experience serious bleeding, for example, after major surgery or trauma. DATA SOURCE...
متن کاملThe evidence behind inhibitor treatment with recombinant factor VIIa.
Over the past 10 years considerable use has been made of recombinant factor VIIa (rFVIIa) for the treatment of patients with inhibitors to coagulation factors. During this time, its place in the management of acute bleeds and surgery has become better defined. Although pharmacokinetic studies report the half-life of rFVIIa as 2.7 h, there is considerable intersubject variability. Moreover, rFVI...
متن کاملChallenges in the therapeutic use of a "so-called" universal hemostatic agent: recombinant factor VIIa.
Recombinant factor VIIa (rFVIIa) was developed in the early 1990s to provide "bypassing" hemostatic therapy for hemophilia A and B patients with inhibitors. More recently, it has been licensed for use in patients with inherited deficiency of factor VII. Since it was licensed for use in hemophilia with inhibitors in the US, Europe, and other countries for these specific indications, it has been ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Critical Care
دوره 9 شماره
صفحات -
تاریخ انتشار 2005